O	0	12	Prophylactic
O	13	16	use
O	17	19	of
B-intervention	20	34	levonorgestrel
I-intervention	34	35	-
I-intervention	35	44	releasing
I-intervention	45	57	intrauterine
I-intervention	58	64	system
O	65	67	in
O	68	73	women
O	74	78	with
O	79	85	breast
O	86	92	cancer
O	93	100	treated
O	101	105	with
O	106	115	tamoxifen
O	115	116	:
O	117	118	a
O	119	129	randomized
O	130	140	controlled
O	141	146	trial
O	146	147	.

O	148	150	To
O	151	159	estimate
O	160	163	the
O	164	168	rate
O	169	171	of
O	172	183	endometrial
O	184	193	pathology
O	194	198	with
O	199	202	the
O	203	215	prophylactic
O	216	219	use
O	220	222	of
O	223	237	levonorgestrel
O	237	238	-
O	238	247	releasing
O	248	260	intrauterine
O	261	267	system
O	268	270	in
O	271	276	women
O	277	281	with
O	282	288	breast
O	289	295	cancer
O	296	303	treated
O	304	308	with
O	309	318	tamoxifen
O	318	319	.

O	320	324	This
O	325	328	was
O	329	330	a
O	331	341	randomized
O	342	348	contro
O	348	349	-
O	349	353	lled
O	354	359	trial
O	360	362	of
B-total-participants	363	366	129
B-ethinicity	367	374	Chinese
O	375	380	women
O	381	384	who
O	385	393	attended
O	394	395	a
O	396	406	university
O	407	415	hospital
O	416	418	in
B-ethinicity	419	423	Hong
I-ethinicity	424	428	Kong
O	429	432	and
B-eligibility	433	441	required
I-eligibility	442	450	adjuvant
I-eligibility	451	460	tamoxifen
I-eligibility	461	464	for
I-eligibility	465	471	breast
I-eligibility	472	478	cancer
I-eligibility	479	484	after
I-eligibility	485	488	the
I-eligibility	489	499	completion
I-eligibility	500	502	of
I-eligibility	503	516	postoperative
I-eligibility	517	529	radiotherapy
I-eligibility	530	533	and
I-eligibility	534	546	chemotherapy
O	546	547	.

O	548	553	Women
O	554	558	were
O	559	569	randomized
O	570	572	to
O	573	582	treatment
O	583	584	(
O	584	596	prophylactic
O	597	611	levonorgestrel
O	611	612	-
O	612	621	releasing
O	622	634	intrauterine
O	635	641	system
O	642	651	insertion
O	652	658	before
O	659	662	the
O	663	675	commencement
O	676	678	of
O	679	688	tamoxifen
O	688	689	)
O	690	692	or
B-control	693	700	control
I-control	701	706	group
O	706	707	.

O	708	711	The
O	712	719	uterine
O	720	726	cavity
O	727	730	was
O	731	739	examined
O	740	742	by
O	743	755	hysteroscopy
O	756	759	and
O	760	771	endometrial
O	772	780	sampling
O	781	787	before
O	788	791	the
O	792	804	commencement
O	805	807	of
O	808	817	tamoxifen
O	818	821	and
O	822	824	at
O	825	827	12
O	827	828	,
O	829	831	24
O	831	832	,
O	833	835	45
O	835	836	,
O	837	840	and
O	841	843	60
O	844	850	months
O	851	860	afterward
O	860	861	.

O	862	865	Any
O	866	877	endometrial
O	878	884	polyps
O	885	887	or
O	888	898	submucosal
O	899	907	fibroids
O	908	912	were
O	913	921	resected
O	922	929	through
O	930	942	hysteroscopy
O	943	945	at
O	946	950	each
O	951	961	assessment
O	962	965	and
O	966	975	specimens
O	976	980	were
O	981	985	sent
O	986	989	for
O	990	1000	histologic
O	1001	1013	confirmation
O	1013	1014	.

O	1015	1016	A
O	1017	1022	total
O	1023	1025	of
B-total-participants	1026	1028	94
O	1029	1034	women
O	1035	1044	completed
O	1045	1046	5
O	1046	1047	-
O	1047	1051	year
O	1052	1058	follow
O	1058	1059	-
O	1059	1061	up
O	1061	1062	.

O	1063	1068	There
O	1069	1072	was
O	1073	1075	no
O	1076	1087	significant
O	1088	1098	difference
O	1099	1101	in
O	1102	1105	the
B-outcome	1106	1116	occurrence
I-outcome	1117	1119	of
I-outcome	1120	1130	submucosal
I-outcome	1131	1139	fibroids
O	1140	1141	(
B-iv-bin-abs	1141	1142	1
O	1143	1144	[
B-iv-bin-percent	1144	1145	1
I-iv-bin-percent	1145	1146	.
I-iv-bin-percent	1146	1147	8
I-iv-bin-percent	1147	1148	%
O	1148	1149	]
O	1150	1158	compared
O	1159	1163	with
B-cv-bin-abs	1164	1165	2
O	1166	1167	[
B-cv-bin-percent	1167	1168	3
I-cv-bin-percent	1168	1169	.
I-cv-bin-percent	1169	1170	4
I-cv-bin-percent	1170	1171	%
O	1171	1172	]
O	1172	1173	)
O	1174	1177	and
B-outcome	1178	1189	endometrial
I-outcome	1190	1201	hyperplasia
O	1202	1203	(
O	1203	1207	both
B-iv-bin-abs	1208	1209	0
O	1209	1210	)
O	1211	1213	in
O	1214	1217	the
O	1218	1227	treatment
O	1228	1231	and
O	1232	1239	control
O	1240	1246	groups
O	1246	1247	,
O	1248	1260	respectively
O	1260	1261	.

O	1262	1276	Levonorgestrel
O	1276	1277	-
O	1277	1286	releasing
O	1287	1299	intrauterine
O	1300	1306	system
O	1307	1320	significantly
O	1321	1328	reduced
B-outcome	1329	1331	de
I-outcome	1332	1336	novo
I-outcome	1337	1348	endometrial
I-outcome	1349	1355	polyps
O	1356	1357	(
O	1357	1363	hazard
O	1364	1369	ratio
O	1370	1371	0
O	1371	1372	.
O	1372	1374	19
O	1374	1375	,
O	1376	1378	95
O	1378	1379	%
O	1380	1390	confidence
O	1391	1399	interval
O	1400	1401	0
O	1401	1402	.
O	1402	1404	07
O	1404	1405	-
O	1405	1406	0
O	1406	1407	.
O	1407	1409	48
O	1409	1410	)
O	1411	1415	over
O	1416	1419	the
O	1420	1426	course
O	1427	1429	of
O	1430	1431	5
O	1432	1437	years
O	1438	1440	on
O	1441	1443	an
O	1444	1453	intention
O	1453	1454	-
O	1454	1456	to
O	1456	1457	-
O	1457	1462	treat
O	1463	1468	basis
O	1468	1469	.

O	1470	1475	There
O	1476	1479	was
O	1480	1482	no
O	1483	1496	statistically
O	1497	1508	significant
O	1509	1517	increase
O	1518	1520	in
B-outcome	1521	1527	breast
I-outcome	1528	1534	cancer
I-outcome	1535	1545	recurrence
I-outcome	1546	1550	rate
O	1551	1552	(
B-cv-bin-abs	1552	1554	10
O	1555	1556	[
B-cv-bin-percent	1556	1558	17
I-cv-bin-percent	1558	1559	.
I-cv-bin-percent	1559	1560	2
I-cv-bin-percent	1560	1561	%
O	1561	1562	]
O	1563	1571	compared
O	1572	1576	with
B-iv-bin-abs	1577	1578	6
O	1579	1580	[
B-iv-bin-percent	1580	1582	10
I-iv-bin-percent	1582	1583	.
I-iv-bin-percent	1583	1584	0
I-iv-bin-percent	1584	1585	%
O	1585	1586	]
O	1586	1587	)
O	1588	1590	or
B-outcome	1591	1597	cancer
I-outcome	1597	1598	-
I-outcome	1598	1605	related
I-outcome	1606	1612	deaths
O	1613	1614	(
B-cv-bin-abs	1614	1615	6
O	1616	1617	[
B-cv-bin-percent	1617	1619	10
I-cv-bin-percent	1619	1620	.
I-cv-bin-percent	1620	1621	3
I-cv-bin-percent	1621	1622	%
O	1622	1623	]
O	1624	1632	compared
O	1633	1637	with
B-iv-bin-abs	1638	1639	5
O	1640	1641	[
B-iv-bin-percent	1641	1642	8
I-iv-bin-percent	1642	1643	.
I-iv-bin-percent	1643	1644	3
I-iv-bin-percent	1644	1645	%
O	1645	1646	]
O	1646	1647	)
O	1648	1650	in
O	1651	1654	the
O	1655	1664	treatment
O	1665	1670	group
O	1670	1671	,
O	1672	1675	but
O	1676	1679	the
O	1680	1685	study
O	1686	1689	was
O	1690	1702	underpowered
O	1703	1705	in
O	1706	1710	this
O	1711	1717	regard
O	1717	1718	.

O	1719	1731	Prophylactic
O	1732	1746	levonorgestrel
O	1746	1747	-
O	1747	1756	releasing
O	1757	1769	intrauterine
O	1770	1776	system
O	1777	1785	prevents
O	1786	1788	de
O	1789	1793	novo
O	1794	1805	endometrial
O	1806	1812	polyps
O	1813	1815	in
O	1816	1821	women
O	1822	1827	using
O	1828	1837	tamoxifen
O	1837	1838	.

O	1839	1846	However
O	1846	1847	,
O	1848	1851	its
O	1852	1856	role
O	1857	1859	in
O	1860	1863	the
O	1864	1874	prevention
O	1875	1877	of
O	1878	1889	endometrial
O	1890	1901	hyperplasia
O	1902	1905	and
O	1906	1920	adenocarcinoma
O	1921	1923	as
O	1924	1928	well
O	1929	1931	as
O	1932	1935	its
O	1936	1942	effect
O	1943	1945	on
O	1946	1950	risk
O	1951	1953	of
O	1954	1960	breast
O	1961	1967	cancer
O	1968	1978	recurrence
O	1979	1985	remain
O	1986	1995	uncertain
O	1995	1996	.

O	1997	2004	Chinese
O	2005	2013	Clinical
O	2014	2019	Trial
O	2020	2028	Registry
O	2028	2029	,
O	2030	2034	http
O	2034	2035	:
O	2035	2036	/
O	2036	2037	/
O	2037	2040	www
O	2040	2041	.
O	2041	2047	chictr
O	2047	2048	.
O	2048	2051	org
O	2051	2052	/
O	2052	2054	en
O	2054	2055	/
O	2055	2056	,
O	2057	2063	ChiCTR
O	2063	2064	-
O	2064	2067	TRC
O	2067	2068	-
O	2068	2076	09000625
O	2076	2077	.

O	2078	2079	I
O	2079	2080	.
